The beneficial effects of dietary fiber (DF) from a behavioral and welfare perspective have been thoroughly studied. However, data on the effects of DF on reproductive performance are scarce. Therefore, the aim of this study was to investigate the impact of increased DF supply during the last 2 wk of gestation on stillbirth rate, preweaning mortality, and total piglet mortality. A total of 644 sows were selected for the experiment from a commercial farm, and the sows were inseminated in weekly batches. Sows in the control group ( = 310) were fed according to the normal feeding strategy of the farm with a gestation diet until 1 wk before expected farrowing, then a transition diet until d 5 of lactation, and then a lactation diet until weaning. Sows in the treatment group ( = 334) were fed as the control group except that 280 g/d of the gestation diet (from d 102 to 108 of gestation) and 570 g/d of the transition diet (from d 109 of gestation until farrowing) was daily replaced with 350 and 700 g/d, respectively, of a DF-rich supplement. Both groups received isocaloric diets on a NE basis. The numbers of live-born and stillborn piglets as well as mortality of live-born piglets with presumed causes of death were recorded. The supplemented DF reduced the proportion of stillborn piglets from 8.8 to 6.6% ( < 0.001) and mortality of total born piglets from 22.3 to 19.9% ( = 0.004) but had no impact on preweaning mortality of the piglets ( = 0.21). Moreover, supplemented DF reduced the proportion of death due to poor viability ( < 0.001; 2.8 vs. 1.5% in the control and treatment groups, respectively) and prevalence of piglet diarrhea ( = 0.004; 0.7 vs. 0.3% in the control and treatment groups, respectively). Crushing, low birth weight, and poor viability were the top 3 contributors to preweaning mortality of live-born piglets, in descending order. In conclusion, the supplemented DF reduced the proportion of stillborn piglets and total piglet mortality as well as mortality due to poor viability and piglet diarrhea in lactation.

Background and ObjectivesThe anti-CD20 antibody ofatumumab is an efficacious therapy for multiple sclerosis (MS) through depletion of B cells. The purpose of this study was to examine the derivative effects of B cell depletion on the peripheral immune system and a direct treatment effect on T cells expressing CD20.MethodsFrequency and absolute numbers of peripheral leukocytes of treatment-naive patients with relapsing-remitting MS (RRMS) and patients treated with ofatumumab for a mean of 482 days were assessed in this observational study by flow cytometry. In addition, effector function and CNS migration of T cells using a human in vitro blood-brain barrier (BBB) assay were analyzed.ResultsThis study showed that ofatumumab treatment of patients with RRMS increased the control of effector T cells and decreased T cell autoreactivity. It also showed that ofatumumab reduced the level of peripheral CD20+ T cells and that the observed decrease in CNS-migratory capacity of T cells was caused by the depletion of CD20+ T cells. Finally, our study pointed out a bias in the measurement of CD20+ cells due to a steric hindrance between the treatment antibody and the flow cytometry antibody.DiscussionThe substantial ofatumumab-induced alteration in the T cell compartment including a severely decreased CNS-migratory capacity of T cells could partly be attributed to the depletion of CD20+ T cells. Therefore, we propose that depletion of CD20+ T cells contributes to the positive treatment effect of ofatumumab and suggests that ofatumumab therapy should be considered a B cell and CD20+ T cell depletion therapy.Classification of EvidenceThis study provides Class IV evidence that compared with treatment-naive patients, ofatumumab treatment of patients with RRMS decreases peripheral CD20+ T cells, increases effector T cell control, and decreases T cell autoreactivity.